Analysis reveals biological activities of schiff bases, indicating potential in drug development.
Schiff bases, first reported by Hugo Schiff in 1864, are condensation products of primary amines with carbonyl compounds, characterized by the azomethine group (RHC=N-R1). The presence of a lone pair of electrons in an sp2 hybridized orbital of the nitrogen atom confers significant chemical and biological properties to these compounds. The versatile nature of Schiff bases stems from their structural flexibility, ease of preparation, and the distinctive properties of the C=N group. Recent advances highlight their broad spectrum of biological activities, including antibacterial, antifungal, antiviral, anticancer, antioxidant, and anticonvulsant properties. Significant developments in synthetic methodologies encompass green chemistry approaches, microwave-assisted synthesis, and mechanochemical methods, offering improved yields and environmental sustainability. Metal complexes of Schiff bases demonstrate enhanced biological activities compared to their parent ligands, particularly in antimicrobial and anticancer applications. Modern synthetic strategies focus on environmentally benign catalysts, solvent-free conditions, and energy-efficient processes. The structural diversity and biological significance of Schiff bases position them as valuable scaffolds in medicinal chemistry and drug development
No takes yet. Share an insight, caveat, or question.
Madaboina et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: